CL2018002438A1 - Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. - Google Patents

Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna.

Info

Publication number
CL2018002438A1
CL2018002438A1 CL2018002438A CL2018002438A CL2018002438A1 CL 2018002438 A1 CL2018002438 A1 CL 2018002438A1 CL 2018002438 A CL2018002438 A CL 2018002438A CL 2018002438 A CL2018002438 A CL 2018002438A CL 2018002438 A1 CL2018002438 A1 CL 2018002438A1
Authority
CL
Chile
Prior art keywords
cancer
vaccine
treatment
composition
skin lesion
Prior art date
Application number
CL2018002438A
Other languages
English (en)
Spanish (es)
Inventor
Tim Ioannides
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of CL2018002438A1 publication Critical patent/CL2018002438A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CL2018002438A 2016-02-27 2018-08-24 Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna. CL2018002438A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06

Publications (1)

Publication Number Publication Date
CL2018002438A1 true CL2018002438A1 (es) 2019-01-04

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002438A CL2018002438A1 (es) 2016-02-27 2018-08-24 Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna.

Country Status (16)

Country Link
EP (1) EP3419661A4 (cg-RX-API-DMAC10.html)
JP (3) JP2019506435A (cg-RX-API-DMAC10.html)
KR (1) KR102873848B1 (cg-RX-API-DMAC10.html)
CN (2) CN122399006A (cg-RX-API-DMAC10.html)
AU (1) AU2017223970B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018067550A2 (cg-RX-API-DMAC10.html)
CA (1) CA3015519A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018002438A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018009205A2 (cg-RX-API-DMAC10.html)
HK (1) HK1256935A1 (cg-RX-API-DMAC10.html)
IL (1) IL261340B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018010338A (cg-RX-API-DMAC10.html)
MY (1) MY194694A (cg-RX-API-DMAC10.html)
SG (1) SG11201807080UA (cg-RX-API-DMAC10.html)
WO (1) WO2017147475A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201805679B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
ES2962700T1 (es) * 2020-10-12 2024-03-20 Hpvvax Llc Composición y método para tratar el cáncer, usando una vacuna como un primer ingrediente activo terapéutico en combinación con un segundo ingrediente activo
CN120302980A (zh) * 2022-10-31 2025-07-11 皮洛杰斯股份有限公司 免疫疗法组合物和使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1572233E (pt) 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
CN107252489A (zh) * 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
AR074485A1 (es) 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
US20130251782A1 (en) 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3054994A4 (en) * 2013-10-13 2017-10-11 The Board of Trustees of the University of Arkansas Human papilloma virus therapeutic vaccine
WO2015106281A1 (en) * 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2965498A1 (en) * 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions

Also Published As

Publication number Publication date
IL261340B1 (en) 2023-03-01
AU2017223970A1 (en) 2018-09-13
IL261340A (en) 2018-11-29
IL261340B2 (en) 2023-07-01
KR102873848B1 (ko) 2025-10-17
MX2018010338A (es) 2018-11-09
JP2019506435A (ja) 2019-03-07
CN108883168A (zh) 2018-11-23
EP3419661A4 (en) 2019-10-23
AU2017223970B2 (en) 2022-01-27
CO2018009205A2 (es) 2018-09-20
EP3419661A1 (en) 2019-01-02
MY194694A (en) 2022-12-15
KR20180112043A (ko) 2018-10-11
CN122399006A (zh) 2026-07-17
JP7732784B2 (ja) 2025-09-02
ZA201805679B (en) 2019-11-27
BR112018067550A2 (pt) 2019-10-01
CA3015519A1 (en) 2017-08-31
JP2021155448A (ja) 2021-10-07
HK1256935A1 (zh) 2019-10-04
JP2023110038A (ja) 2023-08-08
SG11201807080UA (en) 2018-09-27
WO2017147475A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
HK1246183A1 (zh) Hpv疫苗
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX391720B (es) Terapia combinada para tratar cáncer.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
MX2017012982A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MX393601B (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2020001727A (es) Terapia de combinacion.
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CO2018009205A2 (es) Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna
CL2019000846A1 (es) Proteína terapéutica.
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".